Introduction
T h e term 'muscular dystrophy' describes a group of diseases characterized by hereditary progressive muscle weakness and degeneration. Several muscular dystrophies, including certain types of limb-girdle muscular dystrophy (LGMD), are caused by mutations in genes that encode sarcolemmal proteins.
LGMD is genetically and clinically heterogeneous; it may be inherited in an autosomal dominant or recessive manner, and may have different rates of progression and severity. T h e unifying theme among the LGMDs is the initial involvement of the shoulder and pelvic girdle muscles, with relative sparing of most other muscle groups [ 1,2].
T h e nomenclature for LGMD has changed over the years; other terms for this condition have included Duchennelike muscular dystrophy and severe childhood autosomal recessive muscular dystrophy (SCARMD). However, as understanding of the genetic basis of this varied entity progressed, an agreement in nomenclature was achieved [3] ; LGMDl refers to autosomal dominant forms [4-81 and LGMD2 refers to the recessive forms [9-281 (Table 1) .
Among
LGMD2 are four distinct subtypes caused by mutations in sarcoglycan glycoproteins: LGMD2D (a-sarcoglycan) [IS-1 71, LGMD2E (P-sarcoglycan) [18, 19] , LGMDZC (y-sarcoglycan) [20-241, and LGMD2F (6-sarcoglycan) [25, 26] . Together, these glycoproteins form a subcomplex within the larger dystrophin-glycoprotein complex.
Dystrophin-glycoprotein complex
T h e dystrophin-glycoprotein complex (DGC) is a sarcolemmal protein complex that is expressed at high levels in striated muscle [29-321. T h e integral components of the DGC include dystrophin, a large, rod-shaped cytoskeletal protein that binds F-actin [33-35,36"]; a-dystroglycan and P-dystroglycan, which bind the G domain of laminin-2 and the cysteine-rich region of dystrophin [37--391, respectively; the syntrophins, intracellular proteins that bind the C-terminus of dystrophin [40, 41] ; sarcospan, a four-transmembrane domain protein [42']; and the sarcoglycans, as described below [15, 18, 19, 22, 4346] (Fig. 1) . These proteins represent the 'core' DGC; however, there are other proteins that are known to be associated with this complex, but are not found in pure DGC preparations. In addition to different mammalian species, suggesting an important role throughout evolution.
Recently, Ettinger et a/. [65' ] cloned and characterized the complementary DNA for a fifth sarcoglycan, E-sarcoglycan. E-Sarcoglycan shares 44% amino acid identity with a-sarcoglycan, and also has a signal sequence and an extracellular N-terminus. McNally r?t al. [66'] reported that the genomic organization of E-sarcoglycan is identical to that of a-sarcoglycan, and localized the gene to human chromosome 7q21. As yet, no known muscular dystrophy has been mapped to this region, in contrast to the other sarcoglycans. Although it has considerable homology with the other sarcoglycans, E-sarcoglycan is distinguished from the other sarcoglycans by its expression pattern. Whereas a-sarcoglycan, P-sarcoglycan, y-sarcoglycan, and 6sarco-glycan are expressed either exclusively or predominantly in striated muscle, E-sarcoglycan is broadly expressed, and appears to be expressed at high levels in lung. This suggests that E-sarcoglycan may be part of a nonmuscle sarcoglycan complex, possibly with functions similar to those of the DGC.
Sarcoglycan-deficient limb-girdle muscular dystrophy
Subsequent to the initial discovery of the DGC, the hypothesis arose that muscular dystrophy may be caused by mutations in the different DGC components. Several populations with autosomal inheritance of muscular dystrophy had been identified, which excluded diagnoses of X-linked Duchenne and Becker muscular dystrophies. T h e first evidence for a sarcoglycan complex-specific muscular dystrophy arose in the early 1990s, when a SCARMD (now LGMD2C) population in North Africa was shown to have a deficiency of the 50-kDa component of the DGC [67] . Based on this association, this 50-kDa component was dubbed 'adhalin', from the Arabic word for muscle [43] .
Linkage analysis of these families localized the SCARMD locus to chromosome 13q12, and this was initially considered to be the location of the adhalin (now a-sarcoglycan) gene as well [20, 21] . However, SCARMD was shown to be genetically heterogeneous, as families of Brazilian and European descent did not demonstrate linkage to 13q12 [68-701. This was the first indication that LGMD would turn out to be a complex disorder, and also highlighted the range of clinical presentations of the disease, as is discussed below. In 1994, Roberds et al. [IS] reported the primary structure of human a-sarcoglycan and localized the gene to chromosome 17, thus excluding it as the disease gene of the North African SCARMD population. In the same paper, the authors identified missense mutations in a-sarcoglycan in a European family, which represented the first report of muscular dystrophy caused by mutations in a sarcoglycan gene. Since that initial discovery, mutations in other sarcoglycan genes followed in short order. A homozygous missense mutation in P-sarcoglycan was identified in a large Amish pedigree with LGMD2E [18] ; in the same journal, a sporadic case of severe muscular dystrophy with P-sarcoglycan mutations was reported [19] . Simultaneously, the disease gene of the North African LGMD2C population was identified as y-sarcoglycan [22] . Within a year, 6-sarcoglycan was both characterized and implicated in LGMDZF [26, 45, 46] .
T h e sarcoglycan proteins have been shown to form a distinct subcomplex within the larger DGC. These glycoproteins are known to be tightly associated with each other, given the inability to disrupt the complex using detergents such as octyl glucoside [71] and sodium dodecyl sulfate [23] , and the ability of certain subunits to be crosslinked with various agents [71] . In addition, a common immunohistochemical finding in sarcoglycandeficient LGMD is a loss or significant reduction of sarcoglycan components at the sarcolemma [18, 19, 22, 23, 26, 72] , demonstrating that membrane stability or targeting of each sarcoglycan protein is dependent on the integrity of the sarcoglycan complex as a whole. An example of this phenomenon in a LGMD2E patient [18] is illustrated in Fig. 3 . There is also evidence that a-dystroglycan is destabilized at the extracellular surface of muscle fibers, suggesting that the sarcoglycan complex may also be closely associated with dystroglycan [73] . This result has been confirmed in the study of the cardiomyopathic hamster, an animal model of LGMD (see Animal models) [74-761. In addition, subtle abnormalities in dystrophin expression in both LGMD and the cardiomyopathic hamster have been noted [74, 77] .
Little is known about the functional role of the sarcoglycan complex, other than that its integrity is critical for normal muscle physiology. Extensive analysis of LGMD families has resulted in the identification of several mutations, which cause disease ranging in phenotype from mild impairment with slow progression to severe disability and rapid deterioration. T h e diversity of mutations in sarcoglycan-deficient LGMD has been best studied in a-sarcoglycan. In two recent studies, 25 different mutations in 31 unrelated families were reported; together with other reports of sporadic mutations, a total of 39 distinct asarcoglycan mutations have been identified [16,78"] . T h e vast majority of mutations are located in the large extracellular domain, and in particular in exon 3, in which 12 different mutations have been found. Exon 3 also is the location of the most prevalent sarcoglycan mutation, Arg77Cys [78" ]. In the studies mentioned above, this mutation represented nearly a third of all reported chromosomes. In P-sarcoglycan, most of the identified mutations also occur extracellularly, in exons 3 and 4. Fewer y-sarcoglycan mutations have been identified, and only with apparent functional benefit. This suggests that LGMD may be treated symptomatically with steroids to improve muscle function, at least in the less severe cases. Further study of this possibility will be of immense interest to clinicians.
T h e reasons for this variability are not understood. One emerging hypothesis is the idea that the amount of residual expression of the sarcoglycan complex may affect severity [78",89" ]. T h a t is, if a patient has at least low levels of sarcoglycan complex expression, the rate of progression may be somewhat attenuated compared with that in a person with complete deficiency. Thus, in the patients with residual expression, some degree of normal muscle function may be retained, despite the presence of an improperly functioning sarcoglycan complex. One study of LGMD patients [77] demonstrated a possible correlation; however, exceptions were noted within this study. In another study of LGMDZD patients, Eymard et ad. [89" ] demonstrated a relationship between residual a-sarcoglycan expression and disease severity. However, at least one case of early-onset severe LGMDZD with only partial a-sarcoglycan deficiency has been reported, which also argues against this correlation [90] . These recent reports of partial sarcoglycan complex deficiency suggest that the biochemical changes that occur in LGMD are not always uniform. They demonstrate that full immunohistochemical analysis of all sarcoglycan proteins is necessary for a complete asseessment of a patient's LGMD.
Another hypothesis is that specific types of disruptions in secondary structure may have different effects. T h e Arg91Pro mutation in P-sarcoglycan abolishes a charged amino acid and replaces it with a residue that would interrupt a P-sheet. On the other hand, the Arg91Leu mutation would not have a large effect on secondary structure, and would thus result in a milder course of disease [84, 85] . Others have speculated that there may be other genes that affect disease severity [77, 87] , but no clear candidate has arisen. One intriguing possibility is involvement of the muscle-specific calcium-dependent neutral protease calpain 3, in which mutations have been implicated in LGMDZA [ l l ] . This puzzling variability in LGMD presentation remains a problem for future investigation.
As noted above, sarcoglycan complex mutations lead to a reduction of 3-dystroglycan . This would result in a disruption of the dystroglycan-mediated link between the cytoskeleton and the extracellular matrix. Thus, one role of the sarcoglycan complex may be to preserve the integrity of the dystroglycan complex and thereby protect muscle cells from stress associated with muscle contraction. T h e precise nature of this sarcoglycan-dystroglycan interaction is currently unknown.
Sarcoglycans and cardiomyopathy
Recently, evidence has arisen to indicate a possibly important role of the sarcoglycans in the pathogenesis of human cardiomyopathies. Cardiac manifestations are a wellknown consequence of dystrophin mutations [91, 92] , and evidence of sarcoglycan complex disruption in the BIO 14.6 cardiomyopathic hamster, as described below, lent additional support to this hypothesis.
Cases of cardiomyopathy associated with sarcoglycan complex abnormalities have been reported. These are primarily dilated cardiomyopathies, and only in a few cases have the causative mutations been identified [93,94',95 '] (Mora M, Muntoni F, personal communication). Thus far, these patients have initially presented with diagnoses of LGMD, with eventual development of cardiac disease. However, it is possible that some patients may initially present with cardiomyopathy in the absence of skeletal muscle disease, and the presence of LGMD may not be detected. I t is intriguing to speculate what fraction of the so-called 'idiopathic' cardiomyopathy may actually be caused by sarcoglycan complex mutations.
T h e identification of dilated cardiomyopathies with sarcoglycan complex disruptions fits well with a hypothesis proposed by Olson etad. [96' ], who identified cardiac actin mutations in patients with idiopathic dilated cardiomyopathies. T h e authors drew a distinction between dilated and hypertrophic cardiomyopathy, and suggested that dilated cardiomyopathy is caused by defects of force-transmitting proteins, such as actin, and that hypertrophic cardiomyopathy is caused by defects of force-generating proteins, such as myosin and tropomyosin. This suggests that sarcoglycan complex mutations result in a reduced capacity for the DGC to transmit force to the extracellular matrix, causing the observed cases of dilated cardiomyopathy.
Animal models
T h e availability of accurate animal models of muscular dystrophy can greatly facilitate the investigation of hereditary diseases. In the case of sarcoglycan-deficient LGMD, the field has benefited from a naturally occurring model, the BIO 14.6 cardiomyopathic hamster [97] . Although originally identified for its cardiac phenotype, it was known to have skeletal muscle pathology as well. Roberds e~ ad. [74] demonstrated that the muscular dystrophy observed in this animal was caused by apparent defects in the DGC, with an immunohistologic pattern similar to that of LGMD. Others later confirmed this finding, and demonstrated the relative stability of P-dystroglycan at the sarcolemma [75, 98] . Nigro et ad. [99" ] identified a deletion in the 5'-untranslated region of the 6-sarcoglycan gene that results in the loss of an exon specific for skeletal and cardiac muscle, and the loss of the entire sarcoglycan complex. Subsequently, Sakamoto eta/. [I001 reported that the same 8-sarcoglycan deletion may cause either a hypertrophic or dilated cardiomyopathy. In addition, a-dystroglycan appears to be destabilized at the extracellular surface of muscle fibers, which is consistent with the recent finding in one human LGMD patient . Dystrophin was also found to be less tightly associated with the sarcolemma [74] .
These findings in the BIO 14.6 hamster are consistent with those from human LGMDZC-ZE patients, and support one hypothesis of sarcoglycan complex function. Through its interaction with the dystroglycan complex, the sarcoglycan complex serves to stabilize the link between the cytoskeleton and extracellular matrix and protect the sarcolemma from contraction-induced damage. A mutation in any sarcoglycan protein leads to disruption of sarcoglycan complex function and to subsequent dystroglycan complex instability. Thus, the muscle fibers are more susceptible to contraction-induced damage, and muscular dystrophy results (Fig. 4) [54-561. progressive skeletal muscle degeneration, which indicates that this is an accurate model of human LGMD. In the future, it is reasonable to expect the generation of null mice for the other sarcoglycan proteins. Although certain physiologic aspects might be predictable, of particular interest will be the effects that these null mutations have in nonmuscle tissues, given the ubiquitous expression of P-sarcoglycan and 8-sarcoglycan. In addition, these models provide excellent systems in which to test possible therapies, such as pharmacologic intervention or gene transfer.
Gene therapy
As with any hereditary disorder, there is considerable interest regarding the possible development of genetic therapy for the treatment of LGMD. T h e potential for Duchenne muscular dystrophy gene therapy has been extensively studied [102] . Previously, however, similar studies had not been conducted for LGMD, primarily because of uncertainty about the multiple causes of this disease.
Mouse models of LGMD are currently under develop-
Recently, we have demonstrated that, using an adenovirus ment. T h e first mouse knockout of a sarcoglycan gene is that contains the normal 8-sarcoglycan complementary the a-sarcoglycan null mouse [ l o l l . As with the BIO DNA, the skeletal muscle phenotype in the BIO 14.6 14.6 hamster, the disruption of a-sarcoglycan leads to hamster can be corrected via direct intramuscular injection 
